COVID-19 antibody test: Development of a unique high-throughput assay

06. Aug 2020 | 3 min read

COVID-19 antibody test: Development of a unique high-throughput assay

Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology  creates an opportunity to significantly increase capacity for COVID-19/SARS-CoV-2 antibody testing, and importantly, at the same time make SARS-CoV-2 serology tests more easily available and affordable.

Gentian’s PETIA technology offers the benefits of cost-effective open platform testing, with shorter time-to-result and higher throughput compared to other immunoassay systems, perfectly responding to the increasing needs for SARS-CoV-2 antibody testing.

"Many IVD companies have already established COVID-19 antibody tests, however, these tests use assay technologies which usually result in a lower volume throughput. The Gentian antibody test will be a turbidimetric COVID-19 assay using the PETIA technology. The PETIA technology offers the benefits of cost-effective open platform testing, with shorter time-to-result and higher throughput compared to other immunoassay systems, perfectly responding to the envisaged testing needs for COVID-19"

Torsten Knüttel, VP R&D, Gentian

 

PETIA COVID-19/SARS-CoV-2 antibody test in development

Gentian has, over the last few months, worked in close cooperation with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway.

Through this cooperation, we have completed some explorative test work that supports the concept of developing a turbidimetric SARS-CoV-2 antibody test based on Gentian’s proprietary technology. The immunoassay, if successfully developed, will be designed for use on high-throughput clinical chemistry analysers that are available in major laboratories around the world.

covid-patient_web-article2_web-ready

 

Proof-of-concept phase

The project is now in the proof-of-concept phase, with a strong focus on technical feasibility and market assessment to further specify the project and assay development. Subject to fulfillment of the criteria for this phase, the project intention is to undertake a fast track development with a planned launch in 2021.

Gentian has been awarded up to NOK 8.0 million of funding from the Research Council of Norway.

 

Want to know more?

Want to know more about the development of this immunoassay or other products from Gentian, please send an email to marketing@gentian.com or fill out the form below:

 

 

Investor news: https://ewsweb.oslobors.no/message/509241 

You may also read


We are looking for a Quality Specialist to join our team

Nov 25, 2020

We are looking for a Quality Specialist to join our team

We are looking for a Raw Material Quality Specialist at our HQ in Moss, Norway, who will take responsibility..

We are looking for a Process Engineer to join our team

Nov 25, 2020

We are looking for a Process Engineer to join our team

Our production department is looking for a Process Engineer at our HQ in Moss, Norway, who will enjoy taking..

New study results confirm the value of calprotectin in management of COVID-19 patients

Nov 20, 2020

New study results confirm the value of calprotectin in management of COVID-19 patients

New study results from a study conducted in collaboration with Charité – Universitätsmedizin Berlin and Labor..